Purple Biotech (PPBT) Return on Capital Employed (2015 - 2026)
Purple Biotech (PPBT) posted quarterly Return on Capital Employed of 248.21% for Q1 2026, up 22433.0% year-over-year from N/an in Q1 2025, and up 85.91% quarter-over-quarter from 133.51% in Q4 2025.
Purple Biotech (PPBT) Return on Capital Employed (2015 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Return on Capital Employed for 12 consecutive years, with 248.21% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 22433.0% year-over-year to 248.21%; the TTM figure through Mar 2026 stood at 248.21% (up 22433.0% YoY), while the FY2025 annual figure was 140.44%, up 11044.0% from the prior year.
- Return on Capital Employed advanced to 248.21% in Q1 2026 per PPBT's latest filing, from 133.51% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 248.21% in Q1 2026 and bottomed at 16.39% in Q3 2025.
- Historically, Return on Capital Employed has averaged 60.47% across 5 years, with a median of 45.64% in 2022.
- Annual changes were most pronounced in 2025 — Return on Capital Employed slumped 4565 bps — and 2026, when it surged 22433 bps.
- Purple Biotech's Return on Capital Employed stood at 45.64% in 2022, then soared by 39 bps to 63.48% in 2023, then slumped by 46 bps to 34.51% in 2024, then surged by 287 bps to 133.51% in 2025, then jumped by 86 bps to 248.21% in 2026.
- Business Quant data shows PPBT's Return on Capital Employed at 248.21% in Q1 2026, 133.51% in Q4 2025, and 16.39% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Purple Biotech | 133.62 | 133.62 | - | 226.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 248.21% |
| Dec 31, 2025 | 133.51% |
| Sep 30, 2025 | 16.39% |
| Jun 30, 2025 | 17.66% |
| Mar 31, 2025 | 23.88% |
| Dec 31, 2024 | 34.51% |
| Sep 30, 2024 | 54.19% |
| Jun 30, 2024 | 63.30% |
| Mar 31, 2024 | 64.38% |
| Dec 31, 2023 | 63.48% |
| Sep 30, 2023 | 55.93% |
| Jun 30, 2023 | 48.04% |
| Mar 31, 2023 | 42.28% |
| Dec 31, 2022 | 45.64% |
| Sep 30, 2022 | 43.87% |
| Jun 30, 2022 | 37.09% |
| Mar 31, 2022 | 35.66% |
| Dec 31, 2021 | 31.00% |
| Sep 30, 2021 | 29.97% |
| Jun 30, 2021 | 29.08% |